Patents by Inventor William D. Odell

William D. Odell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6139839
    Abstract: A method of controlling, in a warm-blooded animal, an infectious microorganism expressing a chorionic gonadotropin-like growth-regulating protein comprises modulating the activity of the protein by administering to the warm-blooded animal an effective amount of an antibody capable of inhibiting the activity of the protein, the chorionic gonadotropin-like growth-regulating protein itself such that the animal develops a neutralizing immune response, or peptides that block the receptors of the chorionic gonadotropin-like growth-regulating protein in the infectious microorganism. Candida albicans is one such microorganism that can be controlled by delivering an antibody against the growth-regulating protein, CaCGLP. Mycobacteria can also be controlled by this method. A method of inhibiting transition of Candida albicans blastospores in vitro by contacting the blastospores with an antibody against CaCGLP is also disclosed.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: October 31, 2000
    Assignee: University of Utah Research Foundation
    Inventors: William D. Odell, Jeanine T. Griffin, Sanjeev Grover, Omar Caticha, Douglas T. Carrell, Marion L. Woods, II
  • Patent number: 5811249
    Abstract: A method of controlling, in a warm-blooded animal, an infectious microorganism expressing a chorionic gonadotropin-like growth-regulating protein comprises modulating the activity of the protein by administering to the warm-blooded animal an effective amount of an antibody capable of inhibiting the activity of the protein, the chorionic gonadotropin-like growth-regulating protein itself such that the animal develops a neutralizing immune response, or peptides that block the receptors of the chorionic gonadotropin-like growth-regulating protein in the infectious microorganism. Candida albicans is one such microorganism that can be controlled by delivering an antibody against the growth-regulating protein, CaCGLP. Mycobacteria can also be controlled by this method. A method of inhibiting transition of Candida albicans blastospores in vitro by contacting the blastospores with an antibody against CaCGLP is also disclosed.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: September 22, 1998
    Assignee: University of Utah Research Foundation
    Inventors: William D. Odell, Jeanine T. Griffin, Omar Caticha
  • Patent number: 5245016
    Abstract: A protein isolated from Pseudomonas maltophilia is found to possess an exposed, immunologically accessible protein which binds to the FC region of several species of immunoglobulins. The protein is found to bind both IgG and IgA immunoglobulins and is found to have an effective molecular weight of approximately 30,000 daltons. The protein is found to be useful in isolation of IgA immunoglobulins from biological mixtures. The protein makes IgA immunoglobulins available for further analytical techniques, including identifying bacteria which contain IgA binding proteins. Because of the increased availability of IgA immunoglobulins, it is possible to diagnosis and treat IgA-related diseases and their sources.
    Type: Grant
    Filed: April 24, 1991
    Date of Patent: September 14, 1993
    Assignee: University of Utah Research Foundation
    Inventors: William D. Odell, Sanjeev Grover, Zeil A. McGee
  • Patent number: 4150149
    Abstract: This invention is directed to a method and means for the early detection of a wide variety of cancers, in humans, which method and means consists of the assay and development of a pattern or fingerprint of severally biologically inert, or inactive polypeptides (or perhaps biologically active peptides) in the blood of humans, e.g.: big-ACTH (big-Adrenocorticotropin Hormone), big-.beta.MSH (big-beta melanocyte-stimulating Hormone), the alpha chain of the glycopeptide hormones, the measurement of the arginine vasotocin (AVT), an analogue of Arginine vasopressin, (AVP) (or the combined measurement of AVP and AVT). The values obtained by the assays of each of the foregoing polypeptids is then compared with the individual values and patterns found in humans. If any one of the polypeptide values is elevated above the upper end of the normal values, a carcinoma from some tumor site is suspected; also from the pattern of elevations in one or more peptides, a specific type of cancer may be suspected.
    Type: Grant
    Filed: November 29, 1976
    Date of Patent: April 17, 1979
    Assignee: Professional Staff Association of the Los Angeles County Harbor General Hospital
    Inventors: Ada R. Wolfsen, William D. Odell